James B. Johnston

Winnipeg, MB R3A1R9, Canada

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 70 publications

Reduction-Free Thermolysin Digestion Enables Absolute Protein Quantitation in Plasma in 35 min from Sample to Result.

Reduction-Free Thermolysin Digestion Enables Absolute Protein Quantitation in Plasma in 35 min from Sample to Result.

Journal: Journal of proteome research
Published: May 11, 2026

Updated consensus guidelines for the diagnosis and management of patients with HCL and HCL variant.

Updated consensus guidelines for the diagnosis and management of patients with HCL and HCL variant.

Journal: Blood
Published: January 05, 2026

Updated consensus guidelines for the diagnosis and management of patients with hairy cell leukemia (HCL) and HCL-variant.

Updated consensus guidelines for the diagnosis and management of patients with hairy cell leukemia (HCL) and HCL-variant.

Journal: Blood
Published: January 05, 2026

Real-world safety and tolerability of rapid infusion obinutuzumab in chronic lymphocytic leukemia, small lymphocytic lymphoma and non-Hodgkin lymphoma: a provincial review.

Real-world safety and tolerability of rapid infusion obinutuzumab in chronic lymphocytic leukemia, small lymphocytic lymphoma and non-Hodgkin lymphoma: a provincial review.

Journal: Haematologica
Published: August 10, 2025

ATM inhibition decreases ERK activation and is synergistic with ibrutinib in primary chronic lymphocytic leukemia cells.

ATM inhibition decreases ERK activation and is synergistic with ibrutinib in primary chronic lymphocytic leukemia cells.

Journal: Blood advances
Published: July 31, 2024

Lysosome-Disrupting Agents in Combination with Venetoclax Increase Apoptotic Response in Primary Chronic Lymphocytic Leukemia (CLL) Cells Mediated by Lysosomal Cathepsin D Release and Inhibition of Autophagy.

Lysosome-Disrupting Agents in Combination with Venetoclax Increase Apoptotic Response in Primary Chronic Lymphocytic Leukemia (CLL) Cells Mediated by Lysosomal Cathepsin D Release and Inhibition of Autophagy.

Journal: Cells
Published: March 18, 2024

Hairy cell leukemia variant and WHO classification correspondence Re: 5th edition WHO classification haematolymphoid tumors: lymphoid neoplasms.

Hairy cell leukemia variant and WHO classification correspondence Re: 5th edition WHO classification haematolymphoid tumors: lymphoid neoplasms.

Journal: Leukemia
Published: December 04, 2023

Clinical Outcomes in a Large Canadian Centralized CLL Clinic Based on Treatment and Molecular Factors over a Decade.

Clinical Outcomes in a Large Canadian Centralized CLL Clinic Based on Treatment and Molecular Factors over a Decade.

Journal: Current oncology (Toronto, Ont.)
Published: May 13, 2023

A novel method to investigate drug resistance in the chronic lymphocytic leukemia (CLL) microenvironment: Analysis of CLL Cellular Environment and Response (ACCER).

A novel method to investigate drug resistance in the chronic lymphocytic leukemia (CLL) microenvironment: Analysis of CLL Cellular Environment and Response (ACCER).

Journal: Leukemia & lymphoma
Published: February 21, 2023

Venetoclax inhibits autophagy in chronic lymphocytic leukemia cells.

Venetoclax inhibits autophagy in chronic lymphocytic leukemia cells.

Journal: Autophagy reports
Published: February 07, 2023

Elevated expression of interleukin 16 in chronic lymphocytic leukemia is associated with disease burden and abnormal immune microenvironment.

Elevated expression of interleukin 16 in chronic lymphocytic leukemia is associated with disease burden and abnormal immune microenvironment.

Journal: Leukemia research
Published: January 18, 2023

Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia.

Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia.

Journal: Blood cancer journal
Published: September 18, 2022
Showing 1-12 of 70

Last Updated: 09/26/2026